Two types of implantable cardioverter defibrillators can reduce the risk of sudden cardiac death with HCM. Pacemakers and implantable loop recorders also may be options.

An updated edition of the December 16, 2025, article. An aging U.S. population is becoming a first-order driver of consumption reallocation. Going by the data from the United States Census Bureau, by ...

Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year. The ...